In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species
Abstract Micafungin (MCFG) is an echinocandin antifungal agent that exhibits potent activity against most species of Candida and Aspergillus . We investigated the in vitro antifungal combination effects of MCFG with four other antifungal agents — fluconazole (FLCZ), voriconazole (VRCZ), amphotericin...
Gespeichert in:
| Veröffentlicht in: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2009-02, Vol.15 (1), p.1-5 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
| container_volume | 15 |
| creator | Nishi, Isao Sunada, Atsuko Toyokawa, Masahiro Asari, Seishi Iwatani, Yoshinori |
| description | Abstract Micafungin (MCFG) is an echinocandin antifungal agent that exhibits potent activity against most species of Candida and Aspergillus . We investigated the in vitro antifungal combination effects of MCFG with four other antifungal agents — fluconazole (FLCZ), voriconazole (VRCZ), amphotericin B, and flucytosine — against clinical isolates of 54 Candida spp. by checkerboard analysis. The synergistic antifungal effects of MCFG-FLCZ and MCFG-VRCZ were 11% and 15%, respectively, and the latter displayed a synergistic activity of 63% against Candida glabrata . Antagonism was not observed in any of the combinations tested. |
| doi_str_mv | 10.1007/s10156-008-0653-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21087677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1341321X09707111</els_id><sourcerecordid>21087677</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-9b0df4e8f07adc44c400c9b1ed4279f3c60768a1d89cfce252f7aa68f8d350b63</originalsourceid><addsrcrecordid>eNp9ksuKFDEUhgtRnHH0AdxIVq4sPalbEgRBGy8DAy5UcBdSqZOejFVJm6Ra2sfxSU1NtTS4mFVu3_8fcv5TFE8pvKQA7FWkQNuuBOAldG1dinvFOW1qVjLG4X7e1w0t64p-PysexXgDQFnL-cPijIqKQyWq8-LPpSN7m4InyiVrZrdVI9F-6q1TyXpH0BjUKRJvyGS1WgjryC-brokZZ-2d-u1HfEH2PtjTSU27a58wX2X4XT674RY_JB-tQ6K2yrqYiB6ty64jsdGPKuFtnU2m7aBI3KG2GB8XD4waIz45rhfFtw_vv24-lVefP15u3l6VugWRStHDYBrkBpgadNPoBkCLnuLQVEyYWnfAOq7owIU2Gqu2Mkypjhs-1C30XX1RPF99d8H_nDEmOdmocRyVQz9HWVHgrGMsg3QFdfAxBjRyF-ykwkFSkEswcg1G5mDkEowUWfPsaD73Ew4nxTGJDFQrEPOT22KQN34OLn_4TtfXqwhzX_Y2i2LumNM42JBTk4O3d6rf_Kf-F8cPPGA81ZexkiC_LOO0TBMIBoxSWv8F_-7FgA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21087677</pqid></control><display><type>article</type><title>In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Alma/SFX Local Collection</source><creator>Nishi, Isao ; Sunada, Atsuko ; Toyokawa, Masahiro ; Asari, Seishi ; Iwatani, Yoshinori</creator><creatorcontrib>Nishi, Isao ; Sunada, Atsuko ; Toyokawa, Masahiro ; Asari, Seishi ; Iwatani, Yoshinori</creatorcontrib><description>Abstract Micafungin (MCFG) is an echinocandin antifungal agent that exhibits potent activity against most species of Candida and Aspergillus . We investigated the in vitro antifungal combination effects of MCFG with four other antifungal agents — fluconazole (FLCZ), voriconazole (VRCZ), amphotericin B, and flucytosine — against clinical isolates of 54 Candida spp. by checkerboard analysis. The synergistic antifungal effects of MCFG-FLCZ and MCFG-VRCZ were 11% and 15%, respectively, and the latter displayed a synergistic activity of 63% against Candida glabrata . Antagonism was not observed in any of the combinations tested.</description><identifier>ISSN: 1341-321X</identifier><identifier>EISSN: 1437-7780</identifier><identifier>DOI: 10.1007/s10156-008-0653-9</identifier><identifier>PMID: 19280292</identifier><language>eng</language><publisher>Tokyo: Elsevier Ltd</publisher><subject>Amphotericin B ; Amphotericin B - pharmacology ; Antifungal Agents - pharmacology ; Aspergillus ; Candida ; Candida - drug effects ; Candida glabrata ; Candidiasis - microbiology ; Combination effect ; Drug Synergism ; Echinocandins - pharmacology ; Fluconazole ; Fluconazole - pharmacology ; Flucytosine - pharmacology ; Hematology, Oncology and Palliative Medicine ; Humans ; Infectious Diseases ; Lipopeptides - pharmacology ; Medical Microbiology ; Medicine & Public Health ; Micafungin ; Original Article ; Pyrimidines - pharmacology ; Triazoles - pharmacology ; Virology ; Voriconazole</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2009-02, Vol.15 (1), p.1-5</ispartof><rights>Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases</rights><rights>2009 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases</rights><rights>Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-9b0df4e8f07adc44c400c9b1ed4279f3c60768a1d89cfce252f7aa68f8d350b63</citedby><cites>FETCH-LOGICAL-c509t-9b0df4e8f07adc44c400c9b1ed4279f3c60768a1d89cfce252f7aa68f8d350b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10156-008-0653-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10156-008-0653-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19280292$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nishi, Isao</creatorcontrib><creatorcontrib>Sunada, Atsuko</creatorcontrib><creatorcontrib>Toyokawa, Masahiro</creatorcontrib><creatorcontrib>Asari, Seishi</creatorcontrib><creatorcontrib>Iwatani, Yoshinori</creatorcontrib><title>In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><addtitle>J Infect Chemother</addtitle><addtitle>J Infect Chemother</addtitle><description>Abstract Micafungin (MCFG) is an echinocandin antifungal agent that exhibits potent activity against most species of Candida and Aspergillus . We investigated the in vitro antifungal combination effects of MCFG with four other antifungal agents — fluconazole (FLCZ), voriconazole (VRCZ), amphotericin B, and flucytosine — against clinical isolates of 54 Candida spp. by checkerboard analysis. The synergistic antifungal effects of MCFG-FLCZ and MCFG-VRCZ were 11% and 15%, respectively, and the latter displayed a synergistic activity of 63% against Candida glabrata . Antagonism was not observed in any of the combinations tested.</description><subject>Amphotericin B</subject><subject>Amphotericin B - pharmacology</subject><subject>Antifungal Agents - pharmacology</subject><subject>Aspergillus</subject><subject>Candida</subject><subject>Candida - drug effects</subject><subject>Candida glabrata</subject><subject>Candidiasis - microbiology</subject><subject>Combination effect</subject><subject>Drug Synergism</subject><subject>Echinocandins - pharmacology</subject><subject>Fluconazole</subject><subject>Fluconazole - pharmacology</subject><subject>Flucytosine - pharmacology</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Lipopeptides - pharmacology</subject><subject>Medical Microbiology</subject><subject>Medicine & Public Health</subject><subject>Micafungin</subject><subject>Original Article</subject><subject>Pyrimidines - pharmacology</subject><subject>Triazoles - pharmacology</subject><subject>Virology</subject><subject>Voriconazole</subject><issn>1341-321X</issn><issn>1437-7780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ksuKFDEUhgtRnHH0AdxIVq4sPalbEgRBGy8DAy5UcBdSqZOejFVJm6Ra2sfxSU1NtTS4mFVu3_8fcv5TFE8pvKQA7FWkQNuuBOAldG1dinvFOW1qVjLG4X7e1w0t64p-PysexXgDQFnL-cPijIqKQyWq8-LPpSN7m4InyiVrZrdVI9F-6q1TyXpH0BjUKRJvyGS1WgjryC-brokZZ-2d-u1HfEH2PtjTSU27a58wX2X4XT674RY_JB-tQ6K2yrqYiB6ty64jsdGPKuFtnU2m7aBI3KG2GB8XD4waIz45rhfFtw_vv24-lVefP15u3l6VugWRStHDYBrkBpgadNPoBkCLnuLQVEyYWnfAOq7owIU2Gqu2Mkypjhs-1C30XX1RPF99d8H_nDEmOdmocRyVQz9HWVHgrGMsg3QFdfAxBjRyF-ykwkFSkEswcg1G5mDkEowUWfPsaD73Ew4nxTGJDFQrEPOT22KQN34OLn_4TtfXqwhzX_Y2i2LumNM42JBTk4O3d6rf_Kf-F8cPPGA81ZexkiC_LOO0TBMIBoxSWv8F_-7FgA</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>Nishi, Isao</creator><creator>Sunada, Atsuko</creator><creator>Toyokawa, Masahiro</creator><creator>Asari, Seishi</creator><creator>Iwatani, Yoshinori</creator><general>Elsevier Ltd</general><general>Springer Japan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope></search><sort><creationdate>20090201</creationdate><title>In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species</title><author>Nishi, Isao ; Sunada, Atsuko ; Toyokawa, Masahiro ; Asari, Seishi ; Iwatani, Yoshinori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-9b0df4e8f07adc44c400c9b1ed4279f3c60768a1d89cfce252f7aa68f8d350b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Amphotericin B</topic><topic>Amphotericin B - pharmacology</topic><topic>Antifungal Agents - pharmacology</topic><topic>Aspergillus</topic><topic>Candida</topic><topic>Candida - drug effects</topic><topic>Candida glabrata</topic><topic>Candidiasis - microbiology</topic><topic>Combination effect</topic><topic>Drug Synergism</topic><topic>Echinocandins - pharmacology</topic><topic>Fluconazole</topic><topic>Fluconazole - pharmacology</topic><topic>Flucytosine - pharmacology</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Lipopeptides - pharmacology</topic><topic>Medical Microbiology</topic><topic>Medicine & Public Health</topic><topic>Micafungin</topic><topic>Original Article</topic><topic>Pyrimidines - pharmacology</topic><topic>Triazoles - pharmacology</topic><topic>Virology</topic><topic>Voriconazole</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nishi, Isao</creatorcontrib><creatorcontrib>Sunada, Atsuko</creatorcontrib><creatorcontrib>Toyokawa, Masahiro</creatorcontrib><creatorcontrib>Asari, Seishi</creatorcontrib><creatorcontrib>Iwatani, Yoshinori</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nishi, Isao</au><au>Sunada, Atsuko</au><au>Toyokawa, Masahiro</au><au>Asari, Seishi</au><au>Iwatani, Yoshinori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><stitle>J Infect Chemother</stitle><addtitle>J Infect Chemother</addtitle><date>2009-02-01</date><risdate>2009</risdate><volume>15</volume><issue>1</issue><spage>1</spage><epage>5</epage><pages>1-5</pages><issn>1341-321X</issn><eissn>1437-7780</eissn><abstract>Abstract Micafungin (MCFG) is an echinocandin antifungal agent that exhibits potent activity against most species of Candida and Aspergillus . We investigated the in vitro antifungal combination effects of MCFG with four other antifungal agents — fluconazole (FLCZ), voriconazole (VRCZ), amphotericin B, and flucytosine — against clinical isolates of 54 Candida spp. by checkerboard analysis. The synergistic antifungal effects of MCFG-FLCZ and MCFG-VRCZ were 11% and 15%, respectively, and the latter displayed a synergistic activity of 63% against Candida glabrata . Antagonism was not observed in any of the combinations tested.</abstract><cop>Tokyo</cop><pub>Elsevier Ltd</pub><pmid>19280292</pmid><doi>10.1007/s10156-008-0653-9</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-321X |
| ispartof | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2009-02, Vol.15 (1), p.1-5 |
| issn | 1341-321X 1437-7780 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21087677 |
| source | MEDLINE; SpringerLink Journals; Alma/SFX Local Collection |
| subjects | Amphotericin B Amphotericin B - pharmacology Antifungal Agents - pharmacology Aspergillus Candida Candida - drug effects Candida glabrata Candidiasis - microbiology Combination effect Drug Synergism Echinocandins - pharmacology Fluconazole Fluconazole - pharmacology Flucytosine - pharmacology Hematology, Oncology and Palliative Medicine Humans Infectious Diseases Lipopeptides - pharmacology Medical Microbiology Medicine & Public Health Micafungin Original Article Pyrimidines - pharmacology Triazoles - pharmacology Virology Voriconazole |
| title | In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T13%3A12%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20antifungal%20combination%20effects%20of%20micafungin%20with%20fluconazole,%20voriconazole,%20amphotericin%20B,%20and%20flucytosine%20against%20clinical%20isolates%20of%20Candida%20species&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Nishi,%20Isao&rft.date=2009-02-01&rft.volume=15&rft.issue=1&rft.spage=1&rft.epage=5&rft.pages=1-5&rft.issn=1341-321X&rft.eissn=1437-7780&rft_id=info:doi/10.1007/s10156-008-0653-9&rft_dat=%3Cproquest_cross%3E21087677%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21087677&rft_id=info:pmid/19280292&rft_els_id=1_s2_0_S1341321X09707111&rfr_iscdi=true |